Affinity Bio Begins Trial On Cannabis And Diabetic Nerve Pain

An American clinical research organization has announced the launch of a study focused on treating cannabis patients suffering from diabetic nerve pain.

Last week, Affinity Bio Partners announced the start of the clinical study, which is taking place in Pennsylvania.

Approximately half of all diabetic patients experience some peripheral neuropathy, which can stem from high blood sugar.

Diabetic neuropathy, which commonly damages nerves in the feet and legs, can range from numbness of the extremities to problems with the digestive system, urinary tract, blood vessels, and heart.

While some patients may experience mild symptoms, diabetic neuropathy can be very painful and disabling for others.

Patients can manage the progression of diabetic neuropathy through blood sugar management and healthy lifestyle choices.

“I am so excited to be working on this clinical study with Dr. Bryan Doner and the Serena Group,” says Affinity CEO Christina DiArcangelo. “The future of medical cannabis and cannabinoids as medical treatments are dependent upon properly performed clinical studies. It is time for companies to invest their money into performing clinical studies that prove safety and efficacy regarding their products.”

DiArcangelo has worked in biotechnology and the pharmaceutical industry for 22 years and was selected to the Top 100 Registry Business Leaders and Professionals in 2019.

Affinity Bio Partners encouraging patients enrolled in Pennsylvania’s medical cannabis program who suffer from diabetic nerve pain to email or call 724-859-6200 or to check enrollment eligibility at no cost.